AR102879A1 - Métodos para el tratamiento de tumores cerebrales - Google Patents
Métodos para el tratamiento de tumores cerebralesInfo
- Publication number
- AR102879A1 AR102879A1 ARP150103939A ARP150103939A AR102879A1 AR 102879 A1 AR102879 A1 AR 102879A1 AR P150103939 A ARP150103939 A AR P150103939A AR P150103939 A ARP150103939 A AR P150103939A AR 102879 A1 AR102879 A1 AR 102879A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- brain cancer
- methods
- brain tumors
- car
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 3
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oncology (AREA)
Abstract
Una o más secuencias de ácidos nucleicos aisladas que codifican un receptor de antígeno quimérico (CAR) que comprende un receptor de células T que expresa ligandos (por ej un anticuerpo) con antígenos de un cáncer de cerebro. En algunos aspectos, el CAR también expresa uno o más agentes adicionales (útiles para tratar un cáncer de cerebro. También se describen una construcción de expresión, una célula huésped, un método de obtención, un polipéptido, una composición farmacéutica y un método de tratamiento del cáncer de cerebro.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462086346P | 2014-12-02 | 2014-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR102879A1 true AR102879A1 (es) | 2017-03-29 |
Family
ID=56078487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150103939A AR102879A1 (es) | 2014-12-02 | 2015-12-02 | Métodos para el tratamiento de tumores cerebrales |
Country Status (18)
Country | Link |
---|---|
US (2) | US9650428B2 (es) |
EP (1) | EP3227317A4 (es) |
JP (1) | JP2017537622A (es) |
KR (1) | KR20180041087A (es) |
CN (1) | CN107709353A (es) |
AR (1) | AR102879A1 (es) |
AU (1) | AU2015355084A1 (es) |
BR (1) | BR112017011771A2 (es) |
CA (1) | CA2969714A1 (es) |
EA (1) | EA201791210A1 (es) |
HK (1) | HK1251862A1 (es) |
IL (1) | IL252610A0 (es) |
MX (1) | MX2017007272A (es) |
PH (1) | PH12017501031A1 (es) |
SG (2) | SG10202103475XA (es) |
TW (1) | TW201636425A (es) |
UY (1) | UY36418A (es) |
WO (1) | WO2016089916A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2850093B1 (en) | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutic il-13 polypeptides |
AU2015355084A1 (en) | 2014-12-02 | 2017-06-29 | Prospect Chartercare Rwmc, Llc | Methods and compositons for treating cancer |
HUE054201T2 (hu) * | 2015-06-19 | 2021-08-30 | Endres Stefan Prof Dr | PD-1-CD28 fúziós fehérjék és gyógyászatban való alkalmazásuk |
US10975148B2 (en) * | 2015-08-05 | 2021-04-13 | CellabMED Inc. | Chimeric antigen receptors, and T cells in which chimeric antigen receptor is expressed |
US20200095301A1 (en) * | 2016-12-14 | 2020-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
AU2018256436A1 (en) | 2017-04-19 | 2019-11-07 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
JP2021503303A (ja) * | 2017-11-20 | 2021-02-12 | プロスペクト チャーターケア アールダブリュエムシー,エルエルシー ディ/ビー/エイ ロジャー ウィリアムズ メディカル センターProspect Chartercare Rwmc,Llc D/B/A Roger Williams Medical Center | Car−t細胞の機能性を改善するための組成物およびその使用 |
US20210139557A1 (en) * | 2017-12-20 | 2021-05-13 | Poseida Therapeutics, Inc. | Vcar compositions and methods for use |
US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
CN110157674A (zh) * | 2018-02-12 | 2019-08-23 | 深圳宾德生物技术有限公司 | 一种靶向性t淋巴细胞及其制备方法和应用 |
CN110144326A (zh) * | 2018-02-12 | 2019-08-20 | 深圳宾德生物技术有限公司 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
CN108440674A (zh) * | 2018-04-28 | 2018-08-24 | 杭州荣泽生物科技有限公司 | 一种Trop-2特异性嵌合抗原受体细胞制备及其用途 |
EP4210727A1 (en) * | 2020-09-11 | 2023-07-19 | University of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for prevention and treatment of influenza infections |
CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
CN113304267B (zh) * | 2021-06-11 | 2022-03-15 | 河南大学 | 肺癌的治疗靶点及其应用 |
CN114014941B (zh) * | 2022-01-10 | 2022-04-12 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
CN116549667B (zh) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | 一种pas修饰的脂质纳米粒、包含其的药物制剂,及其制备方法和用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965126A (en) * | 1996-03-25 | 1999-10-12 | The Penn State Research Foundation | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
WO2001029233A2 (en) * | 1999-10-20 | 2001-04-26 | The Johns Hopkins University School Of Medicine | Chimeric immunogenic compositions and nucleic acids encoding them |
US20030235555A1 (en) * | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
JP2005518800A (ja) * | 2002-03-01 | 2005-06-30 | ブリストル−マイヤーズ スクイブ カンパニー | 構成的に活性化されたチロシンキナーゼレセプターを発現するトランスジェニック非ヒト哺乳動物 |
US7709625B2 (en) * | 2004-06-10 | 2010-05-04 | The Board Of Regents Of The University Of Texas | Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy |
CA2630334C (en) * | 2005-11-16 | 2013-07-23 | Universidad Nacional Autonoma De Mexico | Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer |
CN101616685B (zh) * | 2006-03-06 | 2013-07-24 | 阿穆尼克斯运营公司 | 非结构化重组聚合物和其应用 |
US20080206139A1 (en) * | 2006-11-03 | 2008-08-28 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
CA2735456C (en) * | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
CA3002192C (en) * | 2010-03-26 | 2023-03-07 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
EP2931893A1 (en) * | 2012-12-13 | 2015-10-21 | Universität Leipzig | T-cell modulation by exon skipping |
EP3300745B9 (en) * | 2013-02-15 | 2020-04-15 | The Regents of the University of California | Chimeric antigen receptor and methods of use thereof |
JP2016513458A (ja) * | 2013-03-10 | 2016-05-16 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | 化学療法耐性免疫細胞 |
WO2015120363A1 (en) * | 2014-02-10 | 2015-08-13 | Emory University | Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer |
AU2015355084A1 (en) | 2014-12-02 | 2017-06-29 | Prospect Chartercare Rwmc, Llc | Methods and compositons for treating cancer |
-
2015
- 2015-12-01 AU AU2015355084A patent/AU2015355084A1/en not_active Abandoned
- 2015-12-01 EP EP15865800.5A patent/EP3227317A4/en not_active Withdrawn
- 2015-12-01 US US14/956,299 patent/US9650428B2/en not_active Expired - Fee Related
- 2015-12-01 EA EA201791210A patent/EA201791210A1/ru unknown
- 2015-12-01 MX MX2017007272A patent/MX2017007272A/es unknown
- 2015-12-01 KR KR1020177018139A patent/KR20180041087A/ko unknown
- 2015-12-01 CN CN201580074883.3A patent/CN107709353A/zh active Pending
- 2015-12-01 WO PCT/US2015/063267 patent/WO2016089916A1/en active Application Filing
- 2015-12-01 SG SG10202103475XA patent/SG10202103475XA/en unknown
- 2015-12-01 SG SG11201704519YA patent/SG11201704519YA/en unknown
- 2015-12-01 JP JP2017529284A patent/JP2017537622A/ja active Pending
- 2015-12-01 CA CA2969714A patent/CA2969714A1/en not_active Abandoned
- 2015-12-01 BR BR112017011771A patent/BR112017011771A2/pt not_active Application Discontinuation
- 2015-12-02 TW TW104140317A patent/TW201636425A/zh unknown
- 2015-12-02 AR ARP150103939A patent/AR102879A1/es unknown
- 2015-12-02 UY UY0001036418A patent/UY36418A/es not_active Application Discontinuation
-
2017
- 2017-05-09 US US15/590,961 patent/US20180072789A1/en not_active Abandoned
- 2017-06-01 IL IL252610A patent/IL252610A0/en unknown
- 2017-06-02 PH PH12017501031A patent/PH12017501031A1/en unknown
-
2018
- 2018-08-16 HK HK18110565.4A patent/HK1251862A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
SG10202103475XA (en) | 2021-05-28 |
IL252610A0 (en) | 2017-07-31 |
US20160151490A1 (en) | 2016-06-02 |
TW201636425A (zh) | 2016-10-16 |
HK1251862A1 (zh) | 2019-04-26 |
UY36418A (es) | 2016-06-30 |
SG11201704519YA (en) | 2017-07-28 |
WO2016089916A1 (en) | 2016-06-09 |
EP3227317A4 (en) | 2018-04-25 |
BR112017011771A2 (pt) | 2018-07-10 |
PH12017501031A1 (en) | 2017-11-27 |
US20180072789A1 (en) | 2018-03-15 |
JP2017537622A (ja) | 2017-12-21 |
KR20180041087A (ko) | 2018-04-23 |
CN107709353A (zh) | 2018-02-16 |
MX2017007272A (es) | 2018-06-06 |
AU2015355084A1 (en) | 2017-06-29 |
EA201791210A1 (ru) | 2017-11-30 |
US9650428B2 (en) | 2017-05-16 |
CA2969714A1 (en) | 2016-06-09 |
EP3227317A1 (en) | 2017-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR102879A1 (es) | Métodos para el tratamiento de tumores cerebrales | |
CO2017010502A2 (es) | Receptores del antígeno quimérico dirigidos al antígeno de maduración de células b | |
ECSP18073836A (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
PH12017501115A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use | |
CO2017010190A2 (es) | Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19 | |
MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
PH12019500193A1 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
BR112019007288A2 (pt) | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente | |
CO2017003408A2 (es) | Anticuerpos y fragmentos de los mismos como agonistas de gitr | |
MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
BR112017013176A2 (pt) | receptores de antígenos quiméricos e métodos para usá-los | |
MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
BR112017003104A2 (pt) | tratamento de câncer usando um receptor antigênico quimérico anti-cd123 | |
EA201790307A1 (ru) | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки | |
BR112017001242A2 (pt) | tratamento de câncer usando um receptor antigênico quimérico a cd33 | |
MY193497A (en) | Anti-myostatin antibodies and methods of use | |
BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
MX2019013587A (es) | Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual. | |
ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
MX2016014189A (es) | Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico. | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
EA202092450A2 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |